Detalles de la búsqueda
1.
Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.
J Eur Acad Dermatol Venereol
; 37(9): 1863-1870, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184290
2.
Expert consensus on the systemic treatment of atopic dermatitis in special populations.
J Eur Acad Dermatol Venereol
; 37(6): 1135-1148, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695072
3.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Br J Dermatol
; 184(3): 437-449, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33000465
4.
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
J Eur Acad Dermatol Venereol
; 35(7): 1562-1568, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33711179
5.
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.
J Eur Acad Dermatol Venereol
; 35(4): 797-806, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533553
6.
Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU.
Allergy
; 73(8): 1724-1734, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29460968
7.
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
J Eur Acad Dermatol Venereol
; 32(7): 1111-1119, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438576
8.
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
J Eur Acad Dermatol Venereol
; 32(3): 403-410, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29055155
9.
Chronic Urticaria: Following Practice Guidelines.
Skin Therapy Lett
; 23(3): 1-4, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29772036
10.
The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.
Allergy
; 72(12): 2005-2016, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28543019
11.
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting.
Br J Dermatol
; 186(4): 726-728, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34748637
12.
The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials.
J Eur Acad Dermatol Venereol
; 31(5): 798-807, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27620704
13.
Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage.
J Eur Acad Dermatol Venereol
; 31(7): 1188-1195, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370534
14.
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Skin Therapy Lett
; 22(2): 1-7, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28329404
15.
Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies.
Br J Dermatol
; 175(3): 464-72, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26991866
16.
Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council.
J Eur Acad Dermatol Venereol
; 30(7): 1115-9, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26969587
17.
The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians' offices.
J Eur Acad Dermatol Venereol
; 30(9): 1567-72, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27168494
18.
Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
J Eur Acad Dermatol Venereol
; 29(8): 1576-81, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25600828
19.
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.
J Eur Acad Dermatol Venereol
; 29(8): 1555-61, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25611084
20.
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
J Eur Acad Dermatol Venereol
; 29(2): 361-366, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24980988